Биология ва тиббиёт муаммолари 2025, №3.1 (162)

Maqola mavzusi

ФИБРОНЕКТИН И ЕГО УЧАСТИЕ В РЕМОДЕЛИРОВАНИИ ПОЧЕЧНОЙ ТКАНИ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК (257-259)

Mualliflar

Карабаева Гулчехра Худойбердиевна

Muassasa

Самаркандский государственный медицинский университет, Республика Узбекистан, г. Самарканд

Annotatsiya

Фибронектин играет ключевую роль в ремоделировании почечной ткани при хронической болезни почек, способствуя воспалению, активации фибробластов и фиброзу. Он рассматривается как перспективная терапевтическая мишень, ингибирование которой может замедлить прогрессирование заболевания и сохранить функцию почек.

Kalit so'zlar

фибронектин, хроническая болезнь почек, почечный фиброз, ремоделирование ткани.

Adabiyotlar

1. Xu X., Tan X., Tam P., et al. Role of MMP-2 and MMP-9 in epithelial–mesenchymal transition and the fibrotic kidney // American Journal of Physiology-Renal Physiolo-gy . – 2016. – Vol. 311, No. 6. – P. F1235–F1245. 2. Liu Y. Cellular and molecular mechanisms of renal fi-brosis // Nature Reviews Nephrology . – 2011. – Vol. 7, No. 12. – P. 684–696. 3. Roberts A.B., Sporn M.B. Transforming growth factor-β: mechanisms of action and regulation // Kidney Interna-tional . – 2013. – Vol. 83, No. 4. – P. 731–742. 4. Zhang C., Long Y., Mu L., et al. Role of matrix metalloproteinases in epithelial-to-mesenchymal transition in renal fibrosis // Cell Adhesion & Migration . – 2016. – Vol. 10, No. 1–2. – P. 101–112. 5. Boor P., Ostendorf T., Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets // Nature Reviews Nephrology . – 2010. – Vol. 6, No. 11. – P. 643–656. 6. LeBleu V.S., Taduri G., O’Connell J., et al. Origin and function of myofibroblasts in kidney fibrosis // Nature Medicine . – 2013. – Vol. 19, No. 8. – P. 1047–1053. 7. Zeisberg M., Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms asso-ciated with tissue fibrosis // American Journal of Physiolo-gy-Cell Physiology . – 2013. – Vol. 304, No. 3. – P. C216–C225. 8. Duffield J.S. Cellular and molecular mechanisms in kid-ney fibrosis // Journal of Clinical Investigation . – 2014. – Vol. 124, No. 6. – P. 2299–2306. 9. Strutz F., Okada H., Lo C.W., et al. Fibronectin expres-sion in the kidney: impact on progression of renal disease // Journal of the American Society of Nephrology . – 2002. – Vol. 13, No. 6. – P. 1673–1684. 10. Frangogiannis N.G. The extracellular matrix in myo-cardial injury, repair, and remodeling // The Journal of Clinical Investigation . – 2017. – Vol. 127, No. 8. – P. 2991–3003. 11. Pickford A.R., Smith A., Hughes A.D., et al. Identifica-tion of a region of human fibronectin involved in fibril assembly // Journal of Molecular Biology . – 2008. – Vol. 381, No. 1. – P. 113–127. 12. Koshikawa M., Nagaoka Y., Ohtani K., et al. pUR4, a synthetic fibronectin-binding peptide, reduces renal fibrosis and inflammation in mouse model of kidney injury // Nephrology Dialysis Transplantation . – 2013. – Vol. 28, No. 3. – P. 592–601. 13. Fattaeva D. R., Rizaev J. A., Rakhimova D. A. Efficiency of Different Modes of Therapy for Higher Sinus after COVID-19 in Chronic Obstructive Pulmonary Disease //Annals of the Romanian Society for Cell Biology. – 2021. – Т. 25. – №. 1. – С. 6378-6383. 14. Rizaev J. A. et al. The need of patients with systemic vasculitis and coronavirus infection in the treatment of periodontal diseases //Applied Information Aspects of Medicine (Prikladnye informacionnye aspekty mediciny). – 2022. – Т. 25. – №. 4. – С. 40-45. 15. Rizaev J. A. et al. Immunological and Clinical Aspects of Oral Inflammatory Diseases in the Development of Postpartum Septic Complications //International Journal of Integrative and Modern Medicine. – 2024. – Т. 2. – №. 12. – С. 253-257.